References
- del Águila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003; 60: 813–819.
- Slutsky AS, Lavery JV. Data safety and monitoring boards. N Engl J Med. 2004; 350: 1143–1147.
- Whitehead J. The Design and Analysis of Sequential Clinical Trials. Ed. Whitehead J. In: J.Wiley and Sons Ltd, ed. 1997.
- Whitehead J. Monotherapy trials: sequential design. Epilepsy Res 2001; 45: 81–87.
- Groeneveld G J, Veldink JH, Van der Tweel I. et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–445.
- Klivenyi P, Ferrante RJ, Matthews RT et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5: 347–350.
- Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52: 854–857.
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–591.
- Pocock SJ. In: J.Wiley and Sons Ltd, ed. Clinical trials. A practical approach. Chichester: 1983.
- PEST 4: Operating manual. The University of Reading (UK), 2000.
- Brinkmann JR, Andres P, Mendoza M, Sanjak M. Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci 1997; 147: 97–111.
- Cudkowicz ME, Shefner JM, Schoenfeld DA et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. xMeurology 2003; 6: 456–464.
- Miller RG, Moore DH, Celinas DF. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–848.
- Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425–1431.